QNCX · Quince Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $6.84M | - | $8.08M | $6.55M | $8.14M | - | $4.92M | $4.15M | $3.70M | - |
| SG&A | $4.27M | - | $3.28M | $3.34M | $4.79M | - | $3.63M | $4.70M | $4.97M | - |
| Total Operating Expenses | $14.59M | - | $13.43M | $10.43M | $14.86M | - | $5.86M | $28.19M | $11.22M | - |
| D&A | $36.0K | - | - | - | $32.0K | - | - | - | $40.0K | - |
| Operating Income | ($14.59M) | - | ($13.43M) | ($10.43M) | ($14.86M) | - | ($5.86M) | ($28.19M) | ($11.22M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | ($5.34M) | - | ($46.0K) | $67.0K | $47.0K | - | $13.0K | $36.0K | $31.0K | - |
| Net Income | $35.91M | - | ($13.44M) | ($16.05M) | ($15.03M) | - | ($5.49M) | ($27.73M) | ($11.15M) | - |
| EPS - Basic | $3.60 | - | ($2.50) | ($3.40) | ($3.40) | - | ($1.30) | ($6.40) | ($2.60) | - |
| EPS - Diluted | $2.88 | - | ($2.50) | ($3.40) | ($3.40) | - | ($1.30) | ($6.40) | ($2.60) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $18.16M | $5.81M | $6.45M | $16.83M | $7.77M | $6.21M | $2.67M | $7.89M | $21.81M | $20.75M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $5.39M | $2.22M | $3.40M | $1.76M | $3.01M | $2.90M | $1.62M | $2.40M | $2.07M | $2.03M |
| Current Assets | $25.58M | $22.90M | $29.20M | $37.34M | $33.83M | $44.04M | $51.72M | $63.44M | $70.44M | $77.44M |
| Total Assets | $26.62M | $93.52M | $109.90M | $117.21M | $107.09M | $114.48M | $126.52M | $134.83M | $159.29M | $167.90M |
| Current Liabilities | $8.77M | $43.23M | $26.04M | $7.47M | $8.36M | $7.28M | $5.42M | $10.32M | $9.84M | $9.57M |
| Long-term Debt | - | $0 | $0 | $16.99M | $15.27M | $14.32M | $14.90M | $13.83M | $13.52M | $13.43M |
| Total Liabilities | $10.95M | $129.24M | $108.84M | $105.47M | $88.51M | $84.33M | $81.59M | $87.86M | $85.11M | $82.82M |
| Stockholders' Equity | $15.67M | ($35.71M) | $1.06M | $11.74M | $18.58M | $30.15M | $44.93M | $46.97M | $74.18M | $85.08M |
| Retained Earnings | ($424.54M) | ($460.45M) | ($420.99M) | ($407.55M) | ($391.50M) | ($376.47M) | ($364.01M) | ($358.52M) | ($330.79M) | ($319.64M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($7.63M) | - | - | - | ($9.60M) | - | - | - | ($8.35M) | - |
| Investing Cash Flow | $12.00M | - | - | - | $10.90M | - | - | - | $8.91M | - |
| Financing Cash Flow | $9.44M | - | - | - | $87.0K | - | - | - | $190.0K | - |
| CapEx | $0 | - | - | - | $148.0K | - | - | - | $39.0K | - |
| Free Cash Flow | ($7.63M) | - | - | - | ($9.75M) | - | - | - | ($8.39M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | -0.21 | - | - | - | 0.65 | - | - | - | 0.75 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | -17.5% | - | - | - | - | - | - | - | - | - |
| Return on assets | 134.9% | - | -12.2% | -13.7% | -14.0% | - | -4.3% | -20.6% | -7.0% | - |
| Return on equity | 229.1% | - | -1269.3% | -136.8% | -80.9% | - | -12.2% | -59.0% | -15.0% | - |
| Return on invested capital | - | - | -1001.9% | -28.7% | -34.7% | - | -7.7% | -36.6% | -10.1% | - |
| Liquidity | ||||||||||
| Current ratio | 2.92 | 0.53 | 1.12 | 5.00 | 4.05 | 6.05 | 9.53 | 6.15 | 7.16 | 8.09 |
| Quick ratio | 2.92 | 0.53 | 1.12 | 5.00 | 4.05 | 6.05 | 9.53 | 6.15 | 7.16 | 8.09 |
| Cash ratio | 2.07 | 0.13 | 0.25 | 2.25 | 0.93 | 0.85 | 0.49 | 0.76 | 2.22 | 2.17 |
| Leverage | ||||||||||
| Debt / Equity | - | 0.00 | 0.00 | 1.45 | 0.82 | 0.48 | 0.33 | 0.29 | 0.18 | 0.16 |
| Debt / Assets | - | 0.00 | 0.00 | 0.14 | 0.14 | 0.13 | 0.12 | 0.10 | 0.08 | 0.08 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.70 | -2.62 | 103.78 | 9.99 | 5.76 | 3.80 | 2.82 | 2.87 | 2.15 | 1.97 |
| Liabilities / Assets | 0.41 | 1.38 | 0.99 | 0.90 | 0.83 | 0.74 | 0.64 | 0.65 | 0.53 | 0.49 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 0.4x | - | - | - | - | - | - | - | - | - |
| P / B | 0.6x | - | 830.4x | 65.6x | 31.5x | - | 7.5x | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 1.8% | - | -129.1% | 63.0% | -32.4% | - | 3.8% | -404.9% | 13.4% | - |
| Net income growth (YoY) | - | - | -144.8% | 42.1% | -34.8% | - | -2.6% | -467.5% | 9.0% | - |
| EPS growth (YoY) | - | - | -92.3% | 46.9% | -30.8% | - | -766.7% | -4471.4% | -261.1% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 21.8% | - | - | - | -16.2% | - | - | - | -126.5% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -15.7% | - | -97.6% | -75.0% | -75.0% | -64.6% | -46.0% | -45.9% | -17.8% | -15.4% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Quince Therapeutics against the 5 most active filers in the same SIC group.